| Identification | Back Directory | [Name]
1H-Benzimidazole-7-carboxamide, 1-ethyl-5-[(2-methoxyacetyl)amino]-N-(phenylmethyl)-2-(3-pyridinyl)- | [CAS]
1060469-90-0 | [Synonyms]
NUCC555
NUCC-555
NUCC 555
1H-Benzimidazole-7-carboxamide, 1-ethyl-5-[(2-methoxyacetyl)amino]-N-(phenylmethyl)-2-(3-pyridinyl)- | [Molecular Formula]
C25H25N5O3 | [MOL File]
1060469-90-0.mol | [Molecular Weight]
443.5 |
| Hazard Information | Back Directory | [Description]
NUCC-555 is a first-in-class activin antagonist. It specifically binds to ALK4, which opens a completely new approach to inhibiting the activity of TGF-beta receptor superfamily members. | [Uses]
NUCC-555 is an activin antagonist. NUCC-555 interacts with Trp25, Trp28, Phe55, Tyr93, Lys103, and Asn107 in the Activin A binding pocket. NUCC-555 blocks Activin A-mediated hepatic stellate cells (HSCs) activation. NUCC-555 promotes liver regeneration and halts fibrosis progression in chronic liver disease models. NUCC-555 inhibits Activin A-mediated ovarian cell proliferation. NUCC-555 decreases FSH levels in ovariectomized mice[1][2]. | [References]
[1] Zhu J, et al. Virtual High-Throughput Screening To Identify Novel Activin Antagonists. J Med Chem. 2015 Jul 23;58(14):5637-48. DOI:10.1021/acs.jmedchem.5b00753
[2] Mekala S, et al. Antagonizing Activin A/p15INK4b Signaling as Therapeutic Strategy for Liver Disease. Cells. 2024 Apr 8;13(7):649. DOI:10.3390/cells13070649 |
|
|